Matthias Guckenberger, Zurich
Stephanie E. Combs, Munich
Daniel Zips,Tübingen
References
1Allemani C, et al: Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385: 977–1010.
2Mitchell MJ, Jain RK, Langer R: Engineering and physical sciences in oncology: challenges and opportunities. Nat Rev Cancer 2017; 17: 659–675.
3Baumann, M, et al: Radiation oncology in the era of precision medicine. Nat Rev Cancer 2016; 16: 234–249.
4Rodemann HP, Datta NR, Bodis S: Molecular radiation biology/oncology and its impact on preclinical and clinical research in radiotherapy. Radiother Oncol 2017; 124: 339–343.
5Kelderman S, Schumacher TN, Haanen JB: Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol 2014; 8: 1132–1139.
6Van Limbergen EJ, et al: Combining radiotherapy with immunotherapy: the past, the present and the future. Br J Radiol 2017; 90: 20170157.
7Kepka L, Socha J: PET-CT use and the occurrence of elective nodal failure in involved field radiotherapy for nonsmall cell lung cancer: a systematic review. Radiother Oncol 2015; 115: 151–156.
8Rasch C, et al: Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999; 43: 57–66.
9Ling CC, et al: Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000; 47: 551–560.
10Lambin P, et al: Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017; 14: 749–762.
11Bogowicz M, et al: Post-radiochemotherapy PET radiomics in head and neck cancer – the influence of radiomics implementation on the reproducibility of local control tumor models. Radiother Oncol 2017; 125: 385–391.
12Chun SG, et al: Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol 2017; 35: 56–62.
13Sheets NC, et al: Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012; 307: 1611–1620.
14Voet PW, et al: Toward fully automated multicriterial plan generation: a prospective clinical study. Int J Radiat Oncol Biol Phys 2013; 85: 866–872.
15Schubert C, et al: Intercenter validation of a knowledge based model for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan Consortium. PLoS One 2017; 12:e0178034.
16Acharya S, et al: Online magnetic resonance image guided adaptive radiation therapy: first clinical applications. Int J Radiat Oncol Biol Phys 2016; 94: 394–403.
17Lax I, et al: Stereotactic radiotherapy of malignancies in the abdomen: methodological aspects. Acta Oncol 1994; 33: 677–683.
18Vansteenkiste J, et al: Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow- up. Ann Oncol 2013; 24(suppl 6):vi89–vi98.
19Chang JY, et al: Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630–637.
20Gomez DR, et al: Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016; 17: 1672–1682.
21Tanadini-Lang S, et al: Nomogram based overall survival prediction in stereotactic body radiotherapy for oligometastatic lung disease. Radiother Oncol 2017; 123: 182–188.
22Kroeze SG, et al: Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 2017; 53: 25–37.
23Meadows AT, et al: Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27: 2356–2362.
24Eaton BR, et al: Clinical outcomes among children with standard-risk medulloblastoma treated with proton and photon radiation therapy: a comparison of disease control and overall survival. Int J Radiat Oncol Biol Phys 2016; 94: 133–138.
25Uhl M, et al: Active raster scanning with carbon ions: reirradiation in patients with recurrent skull base chordomas and chondrosarcomas. Strahlenther Onkol 2014; 190: 686–691.
26Shinoto M, et al: Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2016; 95: 498–504.
27Shinoto M, et al: Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 2013; 119: 45–51.
28Combs SE, et al: Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. Radiother Oncol 2013; 108: 132–135.
Guckenberger M, Combs SE, Zips D (eds): Advances in Radiotherapy.
Prog Tumor Res. Basel, Karger, 2018, vol 44, pp 1–10 (DOI: 10.1159/000486981)
______________________